Evidence map›Paper›PMID 37965467›Full record

ArticleFrontiers in oncology2023

Covid-19, leukemia, and secondary malignancies of the skin - is there a connection: a case report and literature analysis.

Olga Bogomolets, Ewa Rojczyk, Roman Hryshchenko, Catherine Bogomolets, Oleksandr Berezkin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Olga BogomoletsFaculty of Medicine, Academy of Silesia in Katowice, Zabrze, Poland.
Ewa RojczykFaculty of Medicine, Academy of Silesia in Katowice, Zabrze, Poland.
Roman HryshchenkoDermatology Department, Bogomolets Clinic, Kyiv, Lviv, Ukraine.
Catherine BogomoletsDermatology Department, Bogomolets Clinic, Kyiv, Lviv, Ukraine.
Oleksandr BerezkinBogomolets Medical Laboratories, DERMPATHLab, Kyiv, Lviv, Ukraine.
Bogomoletz Institute of Physiology · UAMedical University of Silesia · PLBogomolets National Medical University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a patient who was diagnosed with two melanomas and one skin cancer within two years. Of particular interest was the fact, that at the time these tumors were diagnosed, the patient was already suffering from chronic myeloid leukemia, which developed three months after recovering from Covid-19. From the time of leukemia occurrence, the patient has been taking the tyrosine kinase inhibitor (TKI) - Gleevec. Thus, we took into the account the possibile effect of Gleevec administration on the risk of skin tumor appearance. It was also important to analyze the impact of the SARS-CoV-2 virus and chronic myeloid leukemia on the risk of secondary malignancies. According to so far published data, the direct relationship between Gleevec treatment and the occurrence of skin cancers cannot be proved. However, literature data indicate a direct and indirect relationship between SARS-CoV-2 infection and an increased incidence of carcinogenesis.

Indexed as

basal cell carcinomachronic myeloid leukemiaCovid-19Gleevecmelanoma

Identifiers

PMID37965467
PMCPMC10642172
OpenAlexW4388159782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.